Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAVE: Avelumab + Cetuximab in Pre-treated RAS WT mCRC
NCT04561336Phase 2Completed
- Sponsor
- University of Campania Luigi Vanvitelli
- Start
- Aug 2018
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in metastatic colorectal cancer (mCRC), sponsored by University of Campania Luigi Vanvitelli. Primary endpoint: Overall Survival at 24 months. Started Aug 2018; status: completed.
02
Drugs
avelumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04561336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561336.